Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PBM

Psyence Biomedical Ltd.

Apr 24 • 04:00PM ET

0.7980

Dollar change +0.0380
Percentage change 5.00	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.03	Insider Own	64.90%	Shs Outstand	13.39M	Perf Week	16.99%
Market Cap	10.69M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.70M	Perf Month	-29.38%
Income	1.52M	PEG	-	EPS next Q	-	Inst Own	13.83%	Short Float	7.13%	Perf Quarter	-85.96%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	14.79%	Short Ratio	0.09	Perf Half Y	-92.47%
Book/sh	-0.40	P/B	-	EPS next Y	-	ROA	1.13%	Short Interest	0.34M	Perf Year	-92.02%
Cash/sh	0.01	P/C	118.72	EPS next 5Y	-	ROE	1.27%	52W Range	0.51 - 14.55	Perf YTD	-91.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-94.52%	Beta	-0.06
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	-	Gross Margin	-	52W Low	55.40%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-105.54%	Oper. Margin	0.00%	RSI (14)	39.77	Volatility	12.96% 11.08%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-413.01%	Payout	-	Rel Volume	0.01	Prev Close	0.76
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	3.56M	Price	0.80
SMA20	-12.74%	SMA50	-15.08%	SMA200	-89.44%	Trades		Volume	32,307	Change	5.00%

Apr-17-24 08:00AM	Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR) (GlobeNewswire)
Apr-16-24 11:01AM	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire) -12.61%
11:01AM	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
Apr-08-24 08:00AM	Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
08:00AM	Psyence Biomed Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
08:00AM	Loading…
08:00AM	Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (PR Newswire)
Mar-26-24 11:06AM	Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business (GlobeNewswire)
Mar-18-24 04:05PM	Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin (GlobeNewswire)
Mar-15-24 04:30PM	Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares (GlobeNewswire) -18.87%
Mar-12-24 11:15AM	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study (GlobeNewswire) -30.51%
07:00AM	Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones (GlobeNewswire)
Mar-11-24 07:00AM	Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division (GlobeNewswire) -16.11%
Mar-08-24 03:59PM	Why Is Psyence Biomedical (PBM) Stock Up 90% Today? (InvestorPlace) +66.14%
Mar-06-24 07:00AM	Psyence Biomedical's Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study (GlobeNewswire) +18.60%

Psyence Biomedical Ltd. is a life science biotechnology company. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on June 29, 2023 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBM

Psyence Biomedical Ltd.

Upgrade your FINVIZ experience